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To the Editor, 
 
We were interested to read the study of Cock et al [1] on the clinical sensitivity of 
fecal immunochemical tests (FIT) for the detection of sessile serrated 
adenomas/polyps (SSA/SSP), and their conclusion that FIT have low sensitivity for 
their detection.  
 
Participants in their study were aged over 18 years and underwent colonoscopy in 
South Australia with FIT analyses performed on the OC-Sensor Diana (Eiken 
Chemical Co., Ltd, Tokyo, Japan).  Indications for colonoscopy were heterogeneous, 
and were: positive FIT 519 (27.6%), symptoms 561 (29.8%), surveillance 687 
(36.5%), screening 18 (1.0%), and other 97 (5.2%).  However, it is known that the 
performance outcomes using FIT vary in different clinical settings and different fecal 
hemoglobin concentrations (f-Hb) are used as thresholds. [2,3]  In addition, 
quantitative FIT systems use polyclonal antibodies to the globin moiety of human 
haemoglobin and have different analytical specificities, giving different f-Hb results, 
particularly at low f-Hb. [3,4]  Further, f-Hb varies with sex, being higher in males 
than females, [5,6], and increases with age [5,6] and deprivation [6,7], but these 
effects vary from country to country. [8] 
 
In consequence, here we provide information on the value of FIT in the detection of 
SSA in a more homogeneous population (only those referred from primary care for 
colonoscopy due to lower bowel symptoms), from a different country (Scotland), and 
using a different FIT analytical system (HM-JACKarc, Kyowa Medex Co., Ltd, Tokyo, 
Japan).  
 
Over the first year of our routine use of FIT in primary care (December, 2015 – 
November, 2016), 1,447 patients with a variety of lower bowel symptoms, but not 
participating in a surveillance program, completed a single FIT and colonoscopy: the 
overall prevalence of significant bowel disease was 20.5% (comprising 95 colorectal 
cancer [CRC] {6.6%}, 133 higher-risk adenoma [HRA: a polyp > 10 mm diam or 
more than three polyps, and those with villous characteristics and high grade 
dysplasia] {9.2%}, and 68 inflammatory bowel disease [IBD] {4.7%}). There were 12 
SSA (all proximal) and 176 low-risk adenoma [LRA] (< 10 mm diameter, or less than 
three).  The location, median size, number with f-Hb > 10 µg Hb/g feces, and median 
f-Hb of the SSA, HRA, and LRA are shown in Table 1. 
 
Table 1. Number, median size (mm) with 95% confidence intervals (CI), number with 
fecal hemoglobin concentration (f-Hb) > 10 µg Hb/g feces, median f-Hb (with 95% 
CI) of sessile serrated adenoma, higher-risk adenoma, and low-risk adenoma in 
1447 patients with lower bowel symptoms, all referred from primary care. 
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n  median size, 
mm (95 % CI) 
n with f-
Hb ≥ 10 
µg Hb/g 
feces (%) 
median f-Hb, µg 











All 127** 15 (12.0 - 15.0) 99 (78.0) 42.0 (26.0 - 75.0) 0.0071 
Proximal*** 37 15 (12.1 - 18.0) 27 (73.0) 22.0 (12.2 - 53.5) 0.0657 





All 176 5 (5.0 - 5.0) 107 (60.8) 17.0 (12.0 - 22.5) 0.1362 
Proximal 69 5 (4.0 - 6.0) 37 (53.6) 16.0 (0.0 - 25.1) 0.2725 
Distal 107 5 (5.0 - 6.0) 70 (65.4) 17.0 (12.0 - 25.3) 0.0941 
 
 
* p-value relates to difference in median f-Hb to that of sessile serrated adenomas. 
** six SSA had diam > 10 mm and were therefore originally classified in the group of 
133 higher-risk adenoma, but investigated separately in this analysis. 
*** proximal location is proximal to and including the splenic flexure, distal is distal to 
splenic flexure. 
 
Of the 12 SSA, only four (33.3%) had f-Hb greater than the National Institute for 
Health and Care Excellence (NICE) recommended f-Hb threshold of 10 µg Hb/g 
feces. [9]   Of the 127 HRA and 176 LRA, 100 (78.7%) and 107 (60.5%) had f-Hb 
greater than 10 µg Hb/g feces. Median f-Hb was lower in SSA than HRA and LRA. 
These findings are unsurprising because f-Hb is related to severity of colorectal 
disease and higher f-Hb is found in HRA than LRA, large (> 10 mm) compared with 
small adenoma, and also adenoma displaying high-grade compared with low-grade 
dysplasia. [10]  
 
Our data would add to the observations that, in comparison to adenomas, SSA are 
found less frequently at colonoscopy and, for the various reasons elicited by Cock et 
al., [1] may not be associated with significant f-Hb. Moreover, our data suggest that 
their findings on SSA/SSP are likely to be transferable between clinical settings, over 
geography, and with different FIT systems. 
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